A 2025 editorial surveys cannabis legalization across the Asia-Pacific and North America, documenting rising pediatric poisonings, emergency department visits, and cannabis use disorder after legalization. However, the editorial’s selective citation of harm data and lack of systematic methodology mean its conclusions should be treated as expert opinion, not definitive evidence of causation.

Cannabis legalization is accelerating worldwide, with over 50 countries now permitting some form of regulated medical access, yet the regulatory frameworks governing these markets remain highly uneven. Clinicians, particularly those counseling families and patients with mental health vulnerabilities, need a clear-eyed view of the post-legalization evidence on harms ranging from pediatric poisonings to psychosis-related hospitalizations. This editorial, while limited in its methodology, provides a broad geographic overview of these emerging public health signals at a moment when many jurisdictions in Asia-Pacific are actively debating whether and how to liberalize cannabis policy.

Cannabis legalization has expanded rapidly over the past decade, with more than 50 countries now permitting some form of regulated medical use and several jurisdictions, including Canada and multiple US states, allowing recreational access. This editorial by Ahmad and Haque attempts to synthesize the global policy landscape with particular attention to the Asia-Pacific region, where countries range from full recreational legalization (parts of Australia) to strict prohibition with capital punishment (Singapore, Philippines). The authors frame their analysis around the tension between cannabis’s documented therapeutic applications, including treatment of refractory epilepsy, chemotherapy-induced nausea, and chronic pain, and the emerging public health signals associated with expanded legal access.

The editorial’s most prominent quantitative claims are drawn from previously published studies: a cited systematic review reports a relative risk of 4.31 (95% CI 2.30 to 8.07) for pediatric emergency department visits following cannabis legalization in the US and Canada, and a Canadian meta-analysis documents annual cannabis use prevalence rising from 9% before legalization to 25% after legalization (2018 to 2021). The authors also note increasing rates of adult ED visits for cannabis use disorder, psychosis, and cannabinoid hyperemesis syndrome. However, the editorial does not report absolute baseline rates for these outcomes, does not formally appraise the quality of its cited sources, and treats therapeutic benefits asymmetrically, devoting substantially less attention to them. The authors conclude that robust regulatory frameworks, including potency limits, marketing bans, and standardized laboratory testing, are urgently needed, while acknowledging that long-term outcomes remain unclear.

Cannabis Legalization: The Evidence Is Real, But So Are the Gaps in the Evidence

A fourfold increase in children ending up in emergency rooms after accidentally eating cannabis-infused edibles is exactly the kind of number that demands attention, but it also demands context that this editorial, like most of the policy debate, does not fully provide. Ahmad and Haque have assembled something genuinely useful here: a comparative map of cannabis policy across the Asia-Pacific at a time when many of those jurisdictions are making consequential decisions about legalization. The harm signals they catalogue, including rising pediatric poisonings, increasing rates of cannabis use disorder among older adults, and a correlation between retail outlet density and psychosis-related emergency visits, are drawn from real surveillance data and deserve serious clinical attention. The editorial correctly identifies that the design of legalization, not merely the fact of it, modulates outcomes. That insight alone is worth the read. But the paper’s central methodological problem is that it examines cannabis legalization the way one might review a restaurant by reading only the one-star reviews: you will absolutely learn about real problems, but you will not get an accurate picture of the full experience. Therapeutic benefits, black-market displacement, reductions in criminal justice harm, and improved product safety through regulation receive only perfunctory mention in a paper titled as a “double-edged sword.” A double-edged sword, by definition, requires that both edges be examined with equal rigor.

The quantitative figures cited most prominently, a relative risk of 4.31 for pediatric ED visits and a prevalence jump from 9% to 25%, illustrate a subtler problem. If hospitals begin routinely screening for cannabis use after legalization, the number of “cannabis-related” visits will rise even if nothing else changes, much like finding more coins when you start looking under the couch cushions. Neither the underlying systematic review nor this editorial adequately separates genuine incidence increases from improved ascertainment. Without the absolute baseline rate for pediatric cannabis poisonings, a fourfold relative risk increase could represent a shift from 2 per 100,000 to 8 per 100,000, or from 50 to 200, and the clinical and policy implications of those two scenarios differ enormously. A careful clinician reading this editorial should verify the primary sources before citing these numbers in practice.

What I would tell a patient is straightforward: cannabis legalization has made some products safer and more accessible for real medical needs, but the evidence shows genuine risks, especially for children, pregnant women, and people with mental health vulnerabilities, and the regulatory safeguards that should accompany legalization are still catching up. What I would tell a policymaker is that retail density, potency limits, child-resistant packaging, and marketing restrictions are not peripheral details but core determinants of whether legalization produces net public health benefit or harm. Regulate the design, not merely the fact, of access. A fourfold relative risk increase sounds alarming and may be genuinely important, but without the absolute baseline rate and without correcting for the improved ascertainment that legalization itself produces, we cannot yet tell how much of the post-legalization harm signal is real incidence versus real disclosure.

This editorial sits at the lowest tier of the evidence hierarchy for clinical decision-making: it is expert opinion, not a systematic review or original study. For clinicians working in cannabis medicine, it serves best as a geographic orientation to the policy landscape and a curated list of post-legalization harm signals worth monitoring. It should not be used as a primary reference for patient counseling on specific risks, because the underlying data are presented without quality appraisal and without absolute risk figures that would allow meaningful shared decision-making.

From a pharmacological standpoint, the editorial does not distinguish between harms attributable to high-THC recreational concentrates and those associated with lower-dose medical formulations, a distinction that is clinically critical. Clinicians should note that the rising potency of commercially available products, particularly edibles and concentrates, represents a different risk profile than the standardized medical cannabis preparations used in clinical trials for epilepsy or chronic pain. The one concrete takeaway for practice is this: clinicians in any jurisdiction, regardless of legalization status, should routinely ask about cannabis use, screen for patterns consistent with use disorder, and counsel parents specifically about safe storage and child-resistant packaging for cannabis-containing products in the home.

This is a peer-published editorial in a regional medical journal, combining narrative policy review with expert opinion and selective literature citation. It does not report original data, conduct a systematic search, or apply formal quality assessment to its cited studies. In the evidence hierarchy, editorials rank below case reports, observational studies, and systematic reviews. The single most important inference constraint is that the editorial’s conclusions reflect the authors’ selection and interpretation of sources rather than a reproducible, comprehensive synthesis of available evidence.

The editorial’s findings on pediatric poisonings and rising emergency department visits are broadly consistent with surveillance data from North American public health agencies and previously published systematic reviews. The Canadian prevalence increase it cites aligns with data from Statistics Canada’s National Cannabis Survey, though the magnitude of change (9% to 25%) is larger than some other estimates, possibly reflecting methodological differences. The editorial’s geographic contribution, mapping cannabis policy across the Asia-Pacific, extends the comparative policy analysis begun by Areesantichai and colleagues (2020), whose review of the region’s cannabis landscape is the primary reference for the editorial’s Asia-Pacific sections. Where this editorial diverges from the broader literature is in its relative neglect of studies documenting legalization’s potential public health benefits, including black-market displacement, reduced arrest-related harms, and improved product safety through regulated testing, which have been documented in analyses from Colorado, Washington State, and Uruguay (Pardo, 2014).

The most consequential analytic choice in this editorial is the decision to cite post-legalization harm data without adjusting for, or even substantively discussing, ascertainment bias. After legalization, healthcare providers are more likely to screen for and document cannabis involvement in emergency presentations, and patients are more likely to disclose use when it is legal. A systematic approach that incorporated interrupted time-series designs with ascertainment correction, rather than simple pre-post comparisons of raw counts, could have yielded substantially smaller effect estimates for outcomes like pediatric ED visits and cannabis use disorder diagnoses. Similarly, had the authors applied a balanced systematic search encompassing both benefit and harm outcomes, the editorial’s overall framing and conclusions might have tilted from cautionary toward a more nuanced cost-benefit assessment.

The most likely overinterpretation of this editorial is treating it as evidence that cannabis legalization causes net public health harm. The editorial catalogues a set of real and concerning post-legalization harm signals, but it does not conduct a systematic benefit-harm analysis, does not control for confounders such as ascertainment bias and secular trends, and does not quantify absolute risks. The relative risk of 4.31 for pediatric ED visits, while statistically significant and clinically concerning, is a ratio without a clearly stated denominator: readers cannot determine actual risk without the baseline rate, which this editorial does not provide. Interpreting its cautionary tone as a call for recriminalization would also be a misreading; the authors explicitly advocate for regulation, not prohibition.

This editorial contributes a useful geographic overview of cannabis policy across the Asia-Pacific and a curated catalogue of post-legalization harm signals from North America. It does not establish that legalization causes net harm, does not provide absolute risk data for its most prominent statistics, and does not systematically weigh benefits against risks. For clinicians, the most durable takeaway is that the design of legalization, including retail density, potency limits, and child-resistant packaging, matters at least as much as the decision to legalize itself. This remains expert opinion, not primary evidence.

Does this editorial prove that cannabis legalization is dangerous?

No. This is an opinion piece that selectively cites studies showing post-legalization harms, but it does not conduct a systematic analysis, does not weigh benefits against risks, and does not establish causation. The harm signals it identifies are real and worth monitoring, but they are presented without the absolute risk figures or ascertainment corrections needed to draw definitive conclusions.

Should I be worried about cannabis edibles around my children?

Yes, this is a legitimate concern regardless of legalization status. The editorial cites a fourfold increase in pediatric emergency visits for accidental cannabis ingestion after legalization. Clinicians recommend storing all cannabis products in child-resistant containers, keeping them out of reach and out of sight, and treating them with the same caution as prescription medications or household chemicals.

Does this editorial apply to medical cannabis patients?

Only indirectly. The editorial does not distinguish between harms from high-potency recreational products and those from standardized medical formulations. Patients using physician-supervised medical cannabis at established therapeutic doses face a different risk profile than the general population trends described here. Discuss your specific situation with your healthcare provider.

What does this mean for countries considering legalization?

The editorial’s most actionable insight is that how a country legalizes matters enormously. Regulatory details such as the number and density of retail outlets, product potency limits, advertising restrictions, and standardized laboratory testing appear to influence whether legalization produces more harm or more benefit. The question for policymakers is not simply whether to legalize but how to design the regulatory framework.

Have thoughts on this? Share it: